ACTIVATE:
A Phase 3, Randomized, Multicenter, Double-blind, Placebo-Controlled Study Of Mitapivat In Adults With Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

Hanny Al-Samkari, MD,[1] Frédéric Galactéros, MD, PhD,[2] Andreas Glenthøj, MD,[3] Jennifer A. Rothman, MD,[4] Oliver Andres, MD,[5]

Rachael F. Grace, MD,[6] Morado Arias, MD,[7] D. Mark Layton, MB, BS,[8] Koichi Onodera, MD,[9] Madeleine Verhovsek, MD,[10]

Wilma Barcellini, MD,[11] Malia P. Judge, BS,[12] Vanessa Beynon, MD,[12] Emily Xu, PhD,[12] Peter Hawkins, PhD,[12] Erin Zagadailov, PharmD, MS[12]

Sarah Gheuens, MD, PhD,[12] Eduard J. van Beers, MD[13]

[1]Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States; [2]Unité des Maladies Génétiques du Globule Rouge, CHU Henri Mondor, Créteil, France; [3]Department of Hematology, Rigshospitalet, Copenhagen, Denmark; [4]Duke University Medical Center, Durham, NC, United States; [5]Department of Paediatrics, University of Würzburg, Würzburg, Germany; [6]Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, United States; [7]Hematology Department, Hospital Universitario La Paz, Madrid, Spain; [8]Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom; [9]Tohoku University Hospital, Sendai, Japan; [10]McMaster University, Hamilton, Canada; [11]Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; [12]Agios Pharmaceuticals, Inc., Cambridge, MA, United States; [13]Van Creveldkliniek, Department of Internal Medicine, University Medical Center Utrecht, Utrecht, Netherlands

Disclosures

- This study was funded by Agios Pharmaceuticals, Inc.
- Author conflict of interest disclosures as follows:

  – **Hanny Al-Samkari**: Agios, argenx, Dova, Novartis, Rigel, Sobi – consultancy; Agios, Dova, Amgen – research funding

  – **Frédéric Galactéros**: Addmedica – board membership or advisory committee

  – **Andreas Glenthøj**: Agios, bluebird bio, Celgene, Novartis – consultancy and advisory board member; Alexion – research grant; Novo Nordisk – honoraria

  – **Jennifer A. Rothman**: Pfizer – consultancy; Agios, Novartis, Pfizer – honoraria; Agios, bluebird bio, Novartis, Pfizer – research funding

  – **Oliver Andres**: Agios – Advisory board member

  – **Rachael F. Grace**: Agios, Novartis, Pfizer – research funding; Dova – membership of an entity's Board of Directors or advisory committees

  – **Marta Morado Arias**: Sanofi Genzyme – honoraria and other grants

  – **D. Mark Layton**: Agios, Novartis – consultancy; Agios, Cerus, Novartis – membership of an entity's Board of Directors or advisory committees

  – **Koichi Onodera**: No affiliations

  – **Madeleine Verhovsek**: Vertex – consultancy

  – **Wilma Barcellini**: Agios, Alexion, Novartis – honoraria; Agios – research funding; Bioverativ, Incyte – board membership or advisory committee

  – **Malia P. Judge, Vanessa Beynon, Emily Xu, Peter Hawkins, Erin Zagadailov, Sarah Gheuens**: Agios – employees and shareholders

  – **Eduard J. van Beers**: Agios – advisory board member; Agios, Novartis, Pfizer, RR Mechatronics – research funding

- Underrecognized, rare, hereditary chronic hemolytic anemia[1,2]

- Due to mutations in *PKLR,* resulting in chronic hemolysis[1–4]

- Numerous comorbidities and complications[3–6]

- Current management limited to supportive care and splenectomy[3,7]

- No approved disease-modifying agents

Comorbidities and long-term complications are common and affect multiple organ systems[6]

IRON
- **OVERLOAD**
  - **FERRITIN[2] (47%)**
  - **MRI[3] (82%)**
- **CHELATION (23%)**

ENDOCRINE DISEASE (10%)
- **THYROID DISEASE (5%)**

PULMONARY HYPERTENSION (3%)

CHOLELITHIASIS (45%)
CHOLECYSTECTOMY (40%)

LIVER CIRRHOSIS (3%)

SPLENECTOMY (59%)

OSTEOPENIA/BONE FRACTURES (17%)

EXTRAMEDULLARY HEMATOPOIESIS (9%)

APLASTIC CRISIS (14%)

THROMBOSIS (Overall, 7%) (Post-SPLNX, 11%)

MRI = magnetic resonance imaging; PK = pyruvate kinase; PKR = red blood cell-specific form of pyruvate kinase; *PKLR* = gene encoding the pyruvate kinase liver and red blood cell isozymes.
1. Grace RF, et al. *Am J Hematol*. 2015;90:825–30; 2. Zanella A, et al. *Br J Haematol*. 2005;130:11–25; 3. Grace RF, et al. *Blood*. 2018;131:2183–92; 4. van Beers EJ, et al. *Haematologica*. 2019;104:e51–e3; 5. Boscoe AN, et al. *EJH*. 2020;106:484–92; 6. Grace RF, et al. *Eur J Haematol*. 2018;101:758–765; 7. Grace RF, et al. *Br J Haematol*. 2019;184:721–34.

Mitapivat, an oral pyruvate kinase activator

Healthy RBC, wild-type PKR

Glucose → PKR → Pyruvate → ATP

PK-deficient RBC, mPKR

Glucose → mPKR → Pyruvate → ATP → **HEMOLYSIS**

RBC Post Mitapivat Treatment

Glucose → Pyruvate → ATP

Mitapivat

HEMOLYSIS IMPROVEMENT

ATP = adenosine triphosphate; Hb = hemoglobin; mPKR = mutant PKR; PK = pyruvate kinase; PKR = red blood cell-specific form of pyruvate kinase; RBC = red blood cell.

Key eligibility criteria:
- ≥ 18 yrs of age
- Documented ≥ 2 mutant alleles in *PKLR* (≥ 1 missense mutation)
- Not regularly transfused (≤ 4 transfusion episodes in previous year)
- Baseline Hb ≤ 10 g/dL
- Adequate organ function

Key exclusion criteria:
- Homozygous for R479H mutation or have 2 non-missense mutations, without another missense mutation, in *PKLR*
- Splenectomy during study, or within 12 months of enrollment
- Prior bone marrow or stem cell transplant

Screening

Individualized dose escalation period

Fixed-dose period

Open-label extension period

Mitapivat
Placebo

R[a] 1:1

50 mg BID
20 mg BID
5 mg BID

Optimized mitapivat dose

50 mg BID
20 mg BID
5 mg BID

Mock optimized placebo dose

6 wks | 12 wks | 12 wks

Primary and secondary efficacy endpoints

Primary endpoint: Hb response, defined as ≥ 1.5 g/dL increase in Hb concentration from BL sustained at ≥ 2 scheduled assessments at wks 16, 20, or 24 during fixed-dose period

Key secondary endpoint: Average change from BL in Hb concentration at wks 16, 20, and 24

Other secondary endpoints:
- Average change from BL at wks 16, 20, and 24 in markers of hemolysis: bilirubin, LDH, and haptoglobin levels
- Average change from BL at wks 16, 20, and 24 in markers of hematopoietic activity: reticulocyte percentages (fraction of 1)
- Change from BL at wk 24 in HRQoL PRO scores: PKDIA and PKDD

Statistical testing strategy

Primary Endpoint: **Hemoglobin response**
(Logistic regression/CMH)

If H_{01} is rejected at $\alpha = 0.05$

Key Secondary Endpoint:
Average change from BL in
Hemoglobin
at wks 16, 20, and 24
(MMRM)

If H_{02} is rejected at $\alpha = 0.05$

Average change from BL in
Indirect billirubin
at wks 16, 20, and 24
(MMRM)

If H_{03} is rejected at $\alpha = 0.05$

Average change from BL in
Reticulocyte percentage
at wks 16, 20, and 24
(MMRM)

If H_{04} is rejected at $\alpha = 0.05$

Hochberg Testing Procedure at $\alpha = 0.05$

Change from BL in
PKDIA
at wk 24
(MMRM)

Change from BL in
PKDD weekly mean score
at wk 24
(MMRM)

Average change from BL in
LDH
at wks 16, 20, and 24
(MMRM)

Average change from BL in
Haptoglobin
at wks 16, 20, and 24
(MMRM)

H01: Hb Odds Ratio = 1; H0j: Difference in average of mean change from baseline = 0, for j≥ 2.
BL = baseline; CMH = Cochran-Mantel-Haenszel test; Hb = hemoglobin; HRQoL = health-related quality of life; LDH = lactate dehydrogenase; MMRM = Mixed-Effect Model Repeated Measure; PRO = patient-reported outcomes; PKDD = Pyruvate Kinase Deficiency Diary; PKDIA = Pyruvate Kinase Deficiency Impact Assessment; w ks = w eeks.

Patient disposition

Enrollment:

Assessed for eligibility (N = 102)

Excluded at screening based on protocol eligibility criteria (n = 22)

Randomized 1:1 (N = 80)[a]

Allocation:

Allocated to mitapivat (N = 40)
- Received mitapivat (n = 40)

Allocated to placebo (N = 40)
- Received placebo (n = 39)
- Did not receive placebo (n = 1)

Follow-up:

Discontinued mitapivat (n = 0)

Discontinued placebo (n = 0)

Analysis[b]:

Included in full analysis set (N = 40)
- Included in safety analysis set (N = 40)

Included in full analysis set (N = 40)
- Included in safety analysis set (N = 39)

[a]Disposition for end of randomization reflects the disposition after randomization, but before start of study treatment; [b]Analysis set definitions: full analysis set included all patients who were randomized to treatment; safety analysis set included all patients who received at least 1 dose of study treatment.

Demographics

Patient demographics	Mitapivat N = 40	Placebo N = 40
Age (years)		
Mean (SD)	36.0 (15.2)	37.2 (15.9)
Range	18–70	19–78
Sex, n (%)		
Male	16 (40.0)	16 (40.0)
Female	24 (60.0)	24 (60.0)
Race, n (%)		
White	28 (70.0)	32 (80.0)
Asian	5 (12.5)	3 (7.5)
Native Hawaiian or Other Pacific Islander	1 (2.5)	0
American Indian or Alaska Native	0	0
Black or African American	0	0
Other	0	1 (2.5)
Not reported	6 (15.0)	4 (10.0)
Geographic Region, n (%)		
Western Europe	19 (47.5)	20 (50.0)
North America	15 (37.5)	16 (40.0)
Asia	5 (12.5)	3 (7.5)
Middle East	0	1 (2.5)
Latin America	1 (2.5)	0

NB: Summarized using the full analysis set.
SD = standard deviation.

Baseline characteristics

| Baseline characteristics	Mitapivat N = 40	Placebo N = 40
Hb (g/dL), mean (SD)	8.6 (0.99)	8.5 (0.85)
Ferritin (µg/L), mean (SD)	748 (1116.2)	688 (605.2)
Hemolysis markers, mean (SD)		
Indirect bilirubin (µmol/L)	81.8 (61.32)	89.1 (61.79)
LDH (U/L)	348 (276.0)	260 (140.2)
Haptoglobin (g/L)	0.08 (0.107)	0.08 (0.138)
Reticulocyte (fraction of 1)	0.37 (0.241)	0.40 (0.222)
Prior transfusions, n (%)		
0	29 (72.5)	30 (75.0)
1	8 (20.0)	7 (17.5)
2	0	1 (2.5)
3	3 (7.5)	1 (2.5)
≥4	0	1 (2.5)
Prior splenectomy, n (%)	28 (70.0)	30 (75.0)
Prior cholecystectomy, n (%)	28 (70.0)	30 (75.0)
Prior chelation therapy, n (%)[a]	5 (12.5)	10 (25.0)
DXA T-Score, mean (SD)		
Femoral total[b]	−1.12 (1.081)	−0.79 (1.098)
Adjusted spine	−1.78 (1.104)	−1.14 (1.153)
***PKLR* mutation category**		
Missense/Missense	28 (70.0)	27 (67.5)
Missense/Non-missense	12 (30.0)	13 (32.5)

NB: Summarized based on full analysis set (all patients who were randomized to treatment).
[a]'Yes' if a subject has received chelation therapy within 52 wks (364 days) before first dose of study treatment; [b]femoral neck and total hip combined.
DXA = dual-energy x-ray absorptiometry; Hb = hemoglobin; LDH = lactate dehydrogenase; *PKLR* = gene encoding the pyruvate kinase liver and red blood cell isozymes; SD = standard deviation; wks = weeks.

Mitapivat met the primary endpoint, demonstrating a higher hemoglobin response rate as compared with placebo

	Mitapivat N = 40	Placebo N = 40	Difference[a] (95% CI)	2-sided p-value
Hemoglobin response n (%)	16 (40.0)	0 (0)	39.3 (24.1, 54.6)	< 0.0001

Responder threshold: 1.5 g/dL Hb increase

= Hb responder
= Hb non-responder

Mitapivat (N = 40)

Placebo (N = 40)

Average change from BL[b] in Hb at wks 16, 20, and 24, g/dL

NB: Each bar represents an individual patient randomized to either mitapivat or placebo; summarized based on full analysis set (all patients who were randomized to treatment).
[a]Adjusted difference in response rate for primary endpoint; [b]BL is defined as the average of all screening assessments within 45 (42 + 3) days before randomization for subjects randomized and not dosed or before start of study treatment for subjects randomized and dosed.
BL = baseline; CI = confidence intervals; Hb = hemoglobin; wks = weeks.

11

Mitapivat led to early and sustained improvement in Hb

Average change from BL at wks 16, 20, and 24 in Hb

|	Mitapivat N = 40	Placebo N = 40	Difference in LSM (95% CI)	2-sided p-value
Hb (g/dL), LSM (95% CI)	1.67 (1.26, 2.09)	−0.15 (−0.56, 0.27)	1.82 (1.24, 2.40)	< 0.0001

NB: Summarized based on full analysis set (all patients who were randomized to treatment); BL is defined as the average of all screening assessments within 45 (42 + 3) days before randomization for subjects randomized and not dosed or before start of study treatment for subjects randomized and dosed.
BL = baseline; CI = confidence interval; Hb = hemoglobin; LSM = least-squares mean; SE = standard error; wks = weeks.

12

Mitapivat led to improvements in markers of hemolysis

Average change from BL at wks 16, 20, and 24 in indirect bilirubin

	Mitapivat N = 40	Placebo N = 40	Difference in LSM (95% CI)	2-sided p-value
Indirect bilirubin (µmol/L) LSM (95% CI)	−21.16 (−29.59, −12.72)	5.10 (−3.00, 13.21)	−26.26 (−37.82, −14.70)	< 0.0001

Average change from BL at wks 16, 20, and 24 in LDH

	Mitapivat N = 40	Placebo N = 40	Difference in LSM (95% CI)	2-sided p-value
LDH (U/L) LSM (95% CI)	−91.99 (−124.47, −59.50)	−21.18 (−53.30, 10.94)	−70.81 (−115.88, −25.74)	0.0027

Mitapivat (N = 40)   Placebo (N = 40)

NB: Summarized based on full analysis set (all patients who were randomized to treatment). [a]Baseline is defined as the average of all screening assessments within 45 (42 + 3) days before randomization for subjects randomized and not dosed or before start of study treatment for subjects randomized and dosed.
BL = baseline; CI = confidence interval; LDH = lactate dehydrogenase; LSM = least-squares mean; SE = standard error; Wks = weeks.

13

Mitapivat led to improvements in markers of hemolysis and hematopoiesis

Average change from BL at wks 16, 20, and 24 in haptoglobin

	Mitapivat N = 40	Placebo N = 40	Difference in LSM (95% CI)	2-sided p-value
Haptoglobin (g/L) LSM (95% CI)	0.169 (0.088, 0.251)	0.012 (−0.070, 0.094)	0.158 (0.043, 0.273)	0.0079

Average change from BL at wks 16, 20, and 24 in reticulocyte percentage (fraction of 1)

|	Mitapivat N = 40	Placebo N = 40	Difference in LSM (95% CI)	2-sided p-value
Reticulocyte percentage (fraction of 1) LSM (95% CI)	−0.0973 (−0.1252, −0.0694)	0.0038 (−0.0239, 0.0315)	−0.1011 (−0.1391, −0.0632)	< 0.0001

Mitapivat (N = 40)   Placebo (N = 40)

NB: Summarized based on full analysis set (all patients who were randomized to treatment). [a]Baseline is defined as the average of all screening assessments within 45 (42 + 3) days before randomization for subjects randomized and not dosed or before start of study treatment for subjects randomized and dosed.
BL = baseline; CI = confidence interval; LSM = least-squares mean; SE = standard error; Wks = weeks.

Hemoglobin response was seen across all pre-defined patient subgroups

| Characteristic	Subgroup	Hb response rate, % (n/N)		Difference of Hb response rate with 95% CI[b]
		Mitapivat	Placebo	Favors placebo ← → Favors mitapivat
Overall study population[a]:		**40.0 (16/40)**	**0 (0/40)**	
Average of screening Hb:	< 8.5 g/dL	29.4 (5/17)	0 (0/18)	
	≥ 8.5 g/dL	47.8 (11/23)	0 (0/22)	
PKLR mutation category:	Missense/Missense	50.0 (14/28)	0 (0/27)	
	Missense/Non-missense	16.7 (2/12)	0 (0/13)	
Baseline Hb:	< 8.5 g/dL	31.6 (6/19)	0 (0/21)	
	≥ 8.5 g/dL	47.6 (10/21)	0 (0/19)	
Age at screening:	< 35 years	40.9 (9/22)	0 (0/20)	
	≥ 35 years	38.9 (7/18)	0 (0/20)	
Sex:	Male	25.0 (4/16)	0 (0/16)	
	Female	50.0 (12/24)	0 (0/24)	
Race:	White	46.4 (13/28)	0 (0/32)	
	Other[c]	25.0 (3/12)	0 (0/8)	
Geographic region:	North America	33.3 (5/15)	0 (0/16)	
	Western Europe	47.4 (9/19)	0 (0/20)	
	Rest of the World[c]	33.3 (2/6)	0 (0/4)	
Prior splenectomy:	Yes	21.4 (6/28)	0 (0/30)	
	No	83.3 (10/12)	0 (0/10)	
Prior cholecystectomy:	Yes	35.7 (10/28)	0 (0/30)	
	No	50.0 (6/12)	0 (0/10)	
Prior chelation therapy:	Yes	20.0 (1/5)	0 (0/10)	
	No	42.9 (15/35)	0 (0/30)	

Difference of Hb response rate axis: −40, −20, 0, 20, 40, 60, 80, 100

NB: Summarized based on full analysis set (all patients who were randomized to treatment).
[a]Stratified by the Average of Screening Hb concentrations and PKLR gene mutation category; [b]For overall study population difference is based on Mantel-Haenszel stratum weighted method adjusting for randomization stratification factors; for subgroups difference is based on unstratified analyses; [c]Pre-specified subgroups with ≤10% of the subjects in the full analysis set were pooled (race, Asian and Other were pooled). CI = confidence interval; Hb = hemoglobin; N = number of patients randomized; PKLR = gene encoding the pyruvate kinase liver and red blood cell isozymes.

PKDD and PKDIA were developed to assess and capture changes in symptom burden and HRQoL impact in patients with PK deficiency

In-trial Validation

PKDD
7-item Instrument

Signs and Symptoms

Pyruvate Kinase Deficiency Daily Diary

1. Tiredness at its worst
2. Tired after finishing daily activities
3. Jaundice
4. Bone pain
5. Shortness of breath
6. Energy level at beginning of day
7. Energy level at end of day

Daily Sum Score

Scoring Algorithm

T-score
Mean 50, SD 10
Min 25, Max 76

PKDIA
8-item Instrument

Disease Impacts

Pyruvate Kinase Deficiency Impact Assessment

1. Finishing things you wanted to get done
2. Household activities
3. Negative impact on social activities
4. Negative impact on leisure activities
5. Relationships with friends or family negatively affected
6. Difficulty concentrating
7. Difficulty performing moderate physical activity
8. Needing additional rest or sleep

Sum Score

Scoring Algorithm

T-score
Mean 50, SD 10
Min 30, Max 76

High internal consistency ☑

Excellent retest reliability ☑

Higher score = Higher disease burden

HRQoL = health related quality of life; PK = pyruvate kinase; PKDD = PK deficiency diary; PKDIA = PK deficiency impact assessment; SD = standard deviation.

Statistically significant improvement in change from baseline at Week 24 was demonstrated on PKDD and PKDIA mean weekly score

PRO	Mitapivat		Placebo		LSM[a] Difference	2-sided p-value
	BL Mean (SD)	LSM Change from BL at W24	BL Mean (SD)	LSM Change from BL at W24		
PKDD	50.45 (7.315)	–5.16	47.04 (8.103)	–2.05	–3.11 (95% CI:–5.80, –0.41)	0.0247
PKDIA	49.2 (9.00)	–4.65	48.5 (9.15)	–1.39	–3.25 (95% CI: –6.39, –0.12)	0.0421

NB: Summarized based on full analysis set (all patients who were randomized to treatment). [a]Difference in least square means (LSM) of change from BL at Week 24.
BL = baseline; CI = confidence interval; LSM = least square mean; PK = pyruvate kinase; PKDD = PK deficiency diary; PKDIA = PK deficiency impact assessment; PRO = patient-reported outcomes; SD = standard deviation; W = week.

Safety

Patients, n (%)	Mitapivat N = 40	Placebo N = 39
Any TEAEs	35 (87.5)	35 (89.7)
Treatment-related TEAEs	23 (57.5)	14 (35.9)
Grade ≥ 3 TEAEs	10 (25.0)	5 (12.8)
Grade ≥ 3 treatment-related TEAEs	3 (7.5)	0
Serious TEAEs	4 (10.0)	2 (5.1)
TEAEs leading to dose reduction of study drug	0	0
TEAEs leading to interruption of study drug	0	2 (5.1)
TEAEs leading to discontinuation of study drug	0	0
TEAEs leading to death	0	0

NB: The denominator used to calculate percentages is N, the number of subjects in the Safety Analysis Set within each treatment arm.
TEAE = treatment-emergent adverse event.

Most frequently reported (≥ 10%) Adverse Events in ACTIVATE

Preferred Term	Mitapivat N = 40	Placebo N = 39
Patients with events, n (%)	35 (87.5)	35 (89.7)
Nausea	7 (17.5)	9 (23.1)
Headache	6 (15.0)	13 (33.3)
Nasopharyngitis	5 (12.5)	6 (15.4)
Fatigue	5 (12.5)	4 (10.3)
Back pain	5 (12.5)	3 (7.7)
Diarrhea	4 (10.0)	7 (17.9)
Dizziness	4 (10.0)	3 (7.7)
Abdominal pain	4 (10.0)	2 (5.1)
Arthralgia	4 (10.0)	2 (5.1)
Dyspnea	3 (7.5)	4 (10.3)
Alanine aminotransferase increased	1 (2.5)	6 (15.4)
Initial insomnia	1 (2.5)	4 (10.3)
Upper respiratory tract infection	0	4 (10.3)

NB: Summarized in order of decreasing frequency of subjects with events based on the frequencies observed in any grade for the mitapivat arm. The denominator used to calculate percentages is N, the number of subjects in the Safety Analysis Set within each treatment arm. Subjects with multiple adverse events within a PT were counted only once in that PT. For subjects with multiple occurrences of an adverse event, the adverse event with the worst CTCAE grade was included in the summary. MedDRA Version 23.1 and CTCAE Version 4.03 were used.
TEAE = treatment-emergent adverse event.

Mitapivat has the potential to be the first disease-modifying drug therapy for patients with pyruvate kinase deficiency

- Mitapivat demonstrated sustained improvement in hemolytic anemia in non-regularly transfused patients with PK deficiency
  - 40% in mitapivat group achieved a Hb response compared to 0% in placebo group (2-sided p < 0.0001)
  - Increase in Hb occurred early and was sustained
  - The effect of mitapivat on Hb response compared to placebo was observed consistently across all predefined subgroups
- Statistically significant improvements were also demonstrated for the secondary endpoints, including:
  - Average change from baseline in Hb concentration
  - Average change from baseline in markers of hemolysis and hematopoietic activity
  - Change from baseline in novel, PK deficiency-specific PROs
- Mitapivat was well-tolerated with safety profile consistent with prior studies; no TEAEs leading to discontinuation

Acknowledgements

- We would like to thank the patients taking part in this study

- This study was funded by Agios Pharmaceuticals, Inc.

- Editorial assistance was provided by Onyx Medica, London, UK, and supported by Agios Pharmaceuticals, Inc.